Immuneering Corp (IMRX) Stock Price & Analysis

Immuneering Corp (IMRX) rose 2.54% to USD 4.03 as of June 10, 2026 at 02:21 UTC, according to Nexqual real-time market data.

IMRX last closed at USD 3.93; the session ranged USD 3.91–4.14 on volume of 1,377,274 shares. Market capitalization is $260.73M, with a 52-week range of USD 1.66–10.08 (NGM). Source: Nexqual, June 10, 2026 at 02:21 UTC.

Key Statistics (as of June 10, 2026 at 02:21 UTC)

Technical Analysis (IMRX)

Nexqual's technical model rates IMRX "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:21 UTC.

Analyst Ratings (IMRX)

Wall Street analysts rate IMRX "Strong Buy" based on 6 analysts, with a mean price target of USD 17 (range USD 11–30), per Nexqual as of June 10, 2026 at 02:21 UTC.

Earnings (IMRX)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 02:21 UTC.

Financials & Fundamentals (IMRX)

Source: Nexqual, June 10, 2026 at 02:21 UTC.

Financial Health Score (IMRX)

Nexqual rates Immuneering Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:21 UTC.

Ownership (IMRX)

Source: Nexqual, June 10, 2026 at 02:21 UTC.

Leadership (IMRX)

Immuneering Corp is led by Benjamin J. Zeskind (age 42), Co-Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 02:21 UTC.

Major Backers & Investors (IMRX)

Notable institutional backers of Immuneering Corp include FMR, LLC, Fidelity, Sanofi, according to Nexqual as of June 10, 2026 at 02:21 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 02:21 UTC.

From Immuneering Corp's Latest SEC 10-K Filing (filed 2026-03-06)

Key Strengths & Strategy (as disclosed to the SEC)

• Our Platform Consistent with our approach of weaving bioinformatics and computational biology into every stage of the drug development process, we have developed a proprietary disease-agnostic platform that allows us to leverage human biological data to generate insights that are not constrained by the inherent limitations of conventional approaches or prevailing scientific views.
• Over time, we have developed a proprietary technology platform to facilitate that process and, in early 2018, we began applying the extensive counterintuitive insights from and capabilities of our platform and approach to create a wholly owned pipeline of novel small molecule drug programs, initially focusing on oncology.
• Overview Our DCI platform is enabled by two key elements: • Bioinformatics: our ability to efficiently analyze high-throughput molecular-level biochemical assays, including transcriptomics, genomics and/or proteomics, collectively referred to as Omics data; and • 3D Tumor Modeling: our ability to conduct in vitro studies in our own labs using proprietary humanized 3D tumor growth assays that we believe predict in vivo activity more accurately than traditional 2D cell culture models.
• We began applying our proprietary platform and approach to internally develop our wholly owned pipeline of Deep Cyclic Inhibitors, orally administered small molecule drug programs.

Partnerships

• These different types of biochemical and 3D tumor growth assays each provide us with unique information about the molecular mechanisms of disease biology and drug response and help to guide our translational planning and development. 7 Table of Contents Since our inception, we have partnered with industry-leading pharmaceutical and biotechnology companies to perform a variety of analyses that utilize our expertise in translational bioinformatics.
• In August 2025, we announced a clinical supply agreement with Eli Lilly and Company for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982), which intends to support the evaluation of atebimetinib in combination with olomorasib in a planned clinical trial of patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer who have progressed on prior therapy.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:21 UTC. This page is informational and not investment advice.